5 years ago

Immunocore Raises $75M for Immunotherapy Pipeline Expansion

  • Immunocore, a late-stage biotech company, closes a $75 million Series C funding round led by an existing investor and BlackRock

  • The funds will be used to expand its growing clinical stage pipeline of immunotherapies.

      • ProblemHealthcare

      "Cancer, infectious and autoimmune diseases are difficult to treat and often lead to poor outcomes for patients. Current therapies are often ineffective or have significant side effects."

      Solution

      "Immunocore is developing a new class of immunotherapies called ImmTAX that use T cell receptor (TCR) bispecific molecules to target and destroy diseased cells. This approach has the potential to be more effective and have fewer side effects than existing therapies."

      Covered on